Editas Medicine, Inc. (EDIT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Editas Medicine, Inc. (EDIT) Healthcare & Pipeline Overview

Editas Medicine, Inc. is a clinical-stage biotechnology firm leveraging proprietary CRISPR genome editing technology to develop transformative genomic medicines. Focusing on serious diseases like inherited blindness and blood disorders, the company advances a diverse pipeline including EDIT-101, EDIT-102, and EDIT-301, alongside oncology programs, through strategic collaborations and in-house research efforts.

What Is the Investment Thesis for EDIT?

Editas Medicine, Inc. operates as a clinical-stage biotechnology company with a market capitalization of $407M, reflecting its early-stage development and significant future potential tied to its CRISPR gene editing platform. The investment thesis centers on the advancement of its diverse pipeline of genomic medicines, particularly EDIT-101 for LCA10, EDIT-102 for other inherited retinal diseases, and EDIT-301 for sickle cell disease and beta-thalassemia. Positive clinical trial data readouts for these programs represent significant value catalysts, potentially validating the efficacy and safety of its CRISPR technology. The company's high gross margin of 98.8% suggests efficient management of its early-stage revenue, likely from collaborations, while its negative profit margin of -281.6% and free cash flow of -$0.05 billion are typical for a biotech firm heavily investing in research and development. Strategic alliances with partners like Allergan and AskBio provide external validation, funding, and expertise, mitigating some R&D costs and expanding therapeutic reach. However, the high Beta of 2.14 indicates significant volatility, and the inherent risks of clinical trial failures, regulatory hurdles, and intense competition in the gene editing space remain critical considerations for investors.

Based on FMP financials and quantitative analysis

EDIT Key Highlights

Market Capitalization: $407M, reflecting its valuation as a clinical-stage biotechnology company focused on long-term therapeutic development.

• Gross Margin: 98.8%, indicating strong cost control relative to its early-stage revenue, likely derived from collaboration agreements.
• Profit Margin: -281.6%, characteristic of a biotechnology company in the research and development phase with substantial operational expenses and no commercialized products.
• Free Cash Flow: -$0.05 billion, demonstrating significant ongoing investment in its proprietary gene editing platform and clinical trial programs.
• Beta: 2.14, suggesting higher price volatility compared to the broader market, which is typical for a clinical-stage biotechnology stock with binary event risks.

Who Are EDIT's Competitors?

EDIT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EDIT's Key Strengths?

Proprietary CRISPR gene editing platform with broad therapeutic potential.

• Diverse pipeline addressing multiple high-unmet-need diseases across ocular, hematologic, and oncology areas.
• Strategic collaborations with major pharmaceutical partners providing funding and expertise.
• Experienced leadership team managing 246 employees focused on genomic medicine development.
• Strong gross margin (98.8%) indicating efficient management of early-stage revenue streams.

What Are EDIT's Weaknesses?

Operating at a significant loss with a profit margin of -281.6% and negative free cash flow of -$0.05 billion, typical for a clinical-stage biotech.

• High reliance on successful clinical trial outcomes, which are inherently uncertain and lengthy.
• Early-stage nature of many pipeline programs, requiring substantial further investment and time to reach commercialization.
• High Beta (2.14) indicating significant stock price volatility and sensitivity to market fluctuations.
• No commercialized products, meaning no current product revenue streams.

What Could Drive EDIT Stock Higher?

EDIT catalyst: Release of further clinical data from the Phase 1/2 trial of EDIT-101 for Leber Congenital Amaurosis 10, which could provide additional insights into its safety and efficacy profile.

• Continued progress in the clinical development of EDIT-301 for sickle cell disease and transfusion-dependent beta-thalassemia, with updates on patient enrollment and initial data expected.
• Initiation of new clinical trials or advancement of existing preclinical programs, such as EDIT-102 for Usher Syndrome 2A, signaling pipeline progression.
• Potential announcement of new or expanded strategic collaborations that could provide additional funding, resources, or validation for its gene editing platform.
• Presentation of preclinical data for its gene-edited Natural Killer cell medicines or T-cell therapies for oncology at scientific conferences, indicating progress in its cancer programs.

What Are the Key Risks for EDIT?

Financial-distress signal — its Altman Z-Score of -8.07 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events in ongoing or future studies for EDIT-101, EDIT-102, or EDIT-301, which could halt development or require significant delays.
• Significant capital requirements to fund extensive research and development activities and clinical trials, potentially leading to future equity financing and shareholder dilution.
• Regulatory setbacks or delays in obtaining marketing approvals for its gene-editing therapies from health authorities, impacting commercialization timelines.
• Intense competition within the gene editing and broader biotechnology sectors, potentially limiting market share or requiring increased R&D investment to maintain a competitive edge.
• Challenges to its intellectual property rights or the emergence of superior or more cost-effective gene editing technologies from competitors.

What Are the Growth Opportunities for EDIT?

• Growth opportunity 1: **Advancement of Ocular Disorder Programs**: Editas Medicine's lead program, EDIT-101 for Leber Congenital Amaurosis 10 (LCA10), is in Phase 1/2 clinical trials. Successful progression through these trials and subsequent regulatory approval would unlock a significant market for an inherited childhood blindness with high unmet medical need. Furthermore, the development of EDIT-102 for Usher Syndrome 2A and autosomal dominant retinitis pigmentosa expands its reach within inherited retinal diseases. The global market for inherited retinal diseases is substantial, with gene therapies offering the potential for single-administration, durable treatments, representing a multi-billion dollar opportunity over the next decade as these therapies mature.
• Growth opportunity 2: **Development of Hematologic Disease Therapies**: The company's EDIT-301 program targets sickle cell disease and transfusion-dependent beta-thalassemia, two severe genetic blood disorders. These conditions affect millions globally and represent a significant unmet medical need, with existing treatments often being palliative or requiring complex procedures. Successful clinical development and commercialization of EDIT-301 could position Editas Medicine as a leader in curative genetic therapies for these widespread conditions. The market for sickle cell disease and beta-thalassemia treatments is projected to reach several billion dollars annually, offering a substantial revenue stream upon market entry, potentially within the next five to seven years.
• Growth opportunity 3: **Expansion into Oncology with Gene-Edited Cell Therapies**: Editas Medicine is actively developing gene-edited Natural Killer (NK) cell medicines for solid tumor cancers, as well as alpha-beta T cells and gamma delta T cell therapies for various cancers. The oncology market, particularly for advanced cell therapies, is one of the largest and fastest-growing therapeutic areas. By leveraging its CRISPR platform to enhance the efficacy and safety of these cell therapies, Editas aims to carve out a significant share in the competitive but lucrative cancer treatment landscape. This diversification into oncology provides multiple shots on goal for high-value indications, with initial clinical readouts potentially emerging in the mid-to-late 2020s.
• Growth opportunity 4: **Neurological Disease Program**: The company has an early discovery program focused on developing a therapy for a neurological disease, supported by a research collaboration with Asklepios BioPharmaceutical, Inc. (AskBio). Neurological disorders represent a vast and largely underserved therapeutic area, often lacking effective disease-modifying treatments. Successful identification and development of a gene-editing therapy for a specific neurological condition could open access to a multi-billion dollar market. This early-stage program signifies a long-term growth vector, with significant potential if preclinical research translates into clinical success, likely with a timeline extending beyond 2030 for commercialization.
• Growth opportunity 5: **Strategic Collaborations and Platform Leverage**: Editas Medicine's strategic alliances with companies like Juno Therapeutics, Allergan Pharmaceuticals, and AskBio are crucial growth drivers. These collaborations provide non-dilutive funding, access to specialized expertise, and broader market reach for its CRISPR platform. By partnering, Editas can accelerate the development of its pipeline candidates and validate its technology across diverse therapeutic areas. These partnerships also offer potential milestone payments and royalties, contributing to financial stability and future revenue streams, while allowing the company to focus its internal resources on core research and development activities.

What Threats Does EDIT Face?

• Clinical trial failures or unexpected adverse events, leading to delays or discontinuation of programs.
• Intense competition from other gene editing companies and traditional pharmaceutical firms developing alternative therapies.
• Regulatory hurdles and delays in obtaining approvals from health authorities like the FDA.
• Intellectual property disputes or challenges to its proprietary CRISPR technology.
• Need for substantial additional capital to fund ongoing research and development, potentially leading to dilution for existing shareholders.

What Are EDIT's Competitive Advantages?

• Proprietary CRISPR gene editing platform, offering a foundational technology for precise genetic modifications.
• Extensive intellectual property portfolio surrounding its gene editing tools and therapeutic applications.
• Advanced clinical pipeline targeting high-unmet-need diseases, including ocular and hematologic disorders.
• Strategic collaborations with established pharmaceutical companies, validating its technology and providing resources.
• Expertise in developing both in vivo (e.g., ocular) and ex vivo (e.g., cell therapy) gene editing approaches.

What Does EDIT Do?

Editas Medicine, Inc., incorporated in 2013 under its former name Gengine, Inc. before rebranding in November 2013, is a clinical-stage genome editing company headquartered in Cambridge, Massachusetts. The company is dedicated to developing transformative genomic medicines designed to treat a range of serious diseases that currently have limited or no effective treatments. At the core of its therapeutic approach is a proprietary gene editing platform based on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, which allows for precise modifications to DNA. Editas Medicine's pipeline includes several key programs. EDIT-101 is currently in Phase 1/2 clinical trials for Leber Congenital Amaurosis 10 (LCA10), a severe inherited childhood blindness. Further expanding its ocular pipeline, the company is developing EDIT-102 for Usher Syndrome 2A, a form of retinitis pigmentosa accompanied by hearing loss, and for autosomal dominant retinitis pigmentosa, a progressive retinal degeneration. In the hematology space, EDIT-301 is being developed to address sickle cell disease and transfusion-dependent beta-thalassemia. Beyond these, Editas Medicine is exploring gene-edited Natural Killer cell medicines for solid tumor cancers, alpha-beta T cells for multiple cancers, and gamma delta T cell therapies also targeting cancer. An early discovery program is also underway to develop a therapy for a neurological disease. The company strategically engages in research collaborations, including partnerships with Juno Therapeutics, Inc. for engineered T cells in cancer, Allergan Pharmaceuticals International Limited for ocular disorders, and Asklepios BioPharmaceutical, Inc. (AskBio) for a neurological disease therapy, underscoring its multifaceted approach to drug development and market penetration.

What Products and Services Does EDIT Offer?

• Develops proprietary gene editing therapies based on CRISPR technology.
• Advances EDIT-101 in Phase 1/2 clinical trials for Leber Congenital Amaurosis 10 (inherited childhood blindness).
• Develops EDIT-102 for Usher Syndrome 2A and autosomal dominant retinitis pigmentosa (inherited retinal degenerations).
• Works on EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia.
• Researches gene-edited Natural Killer cell medicines for solid tumor cancers.
• Explores alpha-beta T cells and gamma delta T cell therapies for various cancers.
• Engages in an early discovery program for a neurological disease therapy.
• Collaborates with pharmaceutical partners like Juno Therapeutics, Allergan, and AskBio for specific therapeutic programs.

How Does EDIT Make Money?

• Primarily generates revenue through research and development collaboration agreements, including upfront payments, milestone achievements, and potential royalties on future product sales.
• Invests heavily in internal research and development to advance its proprietary CRISPR gene editing platform and pipeline candidates.
• Aims for future revenue generation through the commercialization of its gene-editing therapies upon successful clinical development and regulatory approval.
• Leverages intellectual property surrounding its CRISPR technology to secure partnerships and maintain a competitive advantage in the gene editing space.

What Industry Does EDIT Operate In?

Editas Medicine operates within the highly innovative and rapidly evolving biotechnology industry, specifically focusing on the burgeoning field of genome editing. The broader biotechnology sector is characterized by significant research and development investments, long development timelines, and high regulatory hurdles, but also holds the potential for transformative therapies for previously untreatable diseases. The gene editing market, propelled by technologies like CRISPR, is a key growth area within biotech, with projections for substantial expansion as more therapies advance through clinical trials. Editas Medicine's positioning is as a pioneer in CRISPR-based medicines, aiming to address genetic diseases at their root cause. The competitive landscape includes other gene editing companies and traditional pharmaceutical firms developing alternative therapies. Editas differentiates itself through its proprietary CRISPR platform and a diversified pipeline targeting both ocular and hematologic disorders, as well as oncology, placing it at the forefront of genetic medicine innovation.

Who Are EDIT's Key Customers?

• Patients suffering from severe genetic diseases such as Leber Congenital Amaurosis 10, Usher Syndrome 2A, sickle cell disease, and beta-thalassemia.
• Oncology patients with various solid tumor and other cancers targeted by gene-edited cell therapies.
• Pharmaceutical and biotechnology companies seeking to license or collaborate on CRISPR-based gene editing technologies for drug development.
• Healthcare providers and institutions that would administer approved gene-editing therapies.

Company Profile

Editas Medicine, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Gilmore O'Neill. EDIT has traded publicly since 2016.

Editas Medicine, Inc. Financial Trajectory

Editas Medicine, Inc. (EDIT) reported $11.9M in revenue for Q2 FY2026, reflecting 320.0% growth compared to the prior quarter. The company recorded a net loss of $18.2M, with diluted EPS of $-0.15. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, EDIT averaged $-0.19 in diluted EPS.

How Editas Medicine, Inc. Is Valued

Editas Medicine, Inc. carries a market capitalization of $407M, placing it in the small-cap category. Analyst price targets span from $4.00 to $4.00, with a consensus of $4.00. At the current price of $2.65, that implies approximately 51% upside potential. Relative to its peer group, EDIT's quantitative score of 13/100 is below the peer average of 77/100.

Key Financial Metrics

Return on assets is -73.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -56.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -43.7%, the inverse of the P/E and a quick read on earnings relative to price.

Editas Medicine, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.07 places it in the distress zone, a signal of elevated financial risk.

Editas Medicine, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 0.7% above estimates on average.

Over the past six months, Editas Medicine, Inc. insiders filed 14 SEC Form 4 transactions — 8 sales and 6 purchases. On net that is roughly 333K shares acquired (about $880K) — insiders putting money in tends to read as conviction.

EDIT Financials

EDIT Latest News

EDIT Analyst Consensus

EDIT MoonshotScore

Related Investment Themes

EDIT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources